Immune-mediated heparin-induced thrombocytopenia (HIT) is an uncommon but serious complication of therapy with heparins. It affects all ages and requires replacement of the causative anticoagulant. However, information on alternative antithrombotic use in children with HIT is limited. This paper reviews 27 published and 7 unpublished case reports of children aged 2 weeks to 17 years treated with danaparoid. Thirty-three suffered from HIT or suspected HIT, and 1 child without HIT had a high bleeding risk. All children had severe underlying problems increasing their thrombotic and/or bleeding risk. HIT diagnosis was confirmed serologically or clinically in 26 cases (78.8%). Danaparoid regimens were similar to those used in adults, but in general, younger children needed higher daily doses of danaparoid to achieve the same target plasma anti-Xa levels than teenagers or adults. Of those with a known outcome 28/33 children (84.8%) survived, 7 having suffered from a serious adverse event. Five deaths occurred including 1 thrombotic and 2 major bleeds. Three of the in total 4 major bleeding events occurred in children undergoing surgery with cardiopulmonary bypass. We conclude that despite the reported adverse events danaparoid can be used as an alternative antithrombotic for children who are intolerant of the heparins, except in cases requiring cardiopulmonary bypass surgery.

Keywords:
Danaparoid, Heparin-induced thrombocytopenia, therapy
1.
Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554–561.
2.
Magnani HN: Orgaran (danaparoid) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997;8:74–81.
3.
Risch L, Fischer JE, Herklotz R, Huber AR: Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcome. Intensive Care Med 2004;30:1615–1624.
4.
Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535–555.
5.
Warkentin TE, Roberts RS, Hirsh J, Kelton JG: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2815–2824.
6.
Schmugge M, Risch L, Huber AR, Benn A, Fischer JE: Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002;109:E10.
7.
Klenner AF, Greinacher A: Heparin-induced thrombocytopenia in children; in Warkentin TE, Greinacher A (eds): Heparin-Induced Thrombocytopenia, ed 3. New York, Marcel Dekker, 2004, pp 553–571.
8.
Chong BH, Castaldi PA: Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets. Br J Haematol 1986;64:347–354.
9.
Greinacher A, Michels I, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: successful therapy of patients after prospective selection of a compatible heparinoid with the heparin-induced platelet activation test (in German). Beitr Infusionsther 1992;30:408–412.
10.
Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud- Debayle E, Dreyfus M, Meyer D: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21–28.
11.
Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27–30.
12.
Girisch M, Buheitel G, Ries M, Klinge J: Safe and effective use of danaparoid during cardiac catheterization in a 14 month old boy with tetralogy of Fallot and heparin-induced thrombocytopenia (abstract 68). Ann Hematol 2001;80(suppl):A20.
13.
Teien AN, Lie M: Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977;10:399–410.
14.
von Roth B, Herkenrath P, Krebber J, Anschütz K: Use of a new heparinoid as the sole anticoagulant in haemodialysis of paediatric patients (in German). Nieren Hochdruckkrankheiten 1985;14:164.
15.
Barth KSA: Incidence of the Heparin-Induced Thrombocytopenia at the Justus Liebig University Hospital (in German); MD thesis Justus Liebig University, Giessen, 1998.
16.
Bocquet R, Blanot S, Dautzenberg MD, Pierre-Kahn A, Carli P: Antiphospholipid antibody syndrome in pediatric neurosurgery: a haemostasis problem (in French). Ann Fr Anesth Reanim 1999;18:991–995.
17.
Klement D, Rammos S, von Kries R, Kirschke W, Kniemeyer HW, Greinacher A: Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996;155:11–14.
18.
Neuhaus TJ, Goetschel P, Schmugge M, Leumann E: Heparin-induced thrombocytopenia type II on haemodialysis: switch to danaparoid. Pediatr Nephrol 2000;14:713–716.
19.
Schiffmann H, Unterhalt M, Harms K, Figulla HR, Völpel H, Greinacher A: Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin (in German). Monatsschr Kinderheilkd 1997;145:606–612.
20.
Sauer M, Gruhn B, Fuchs D, Altermann W, Zintl F: Heparin-induced thrombocytopenia type II during high-dose chemotherapy with stem-cell-rescue (in German). Klin Pädiatr 1998;210:102–105.
21.
Weigel B, Laskey A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M: Danaparoid (orgaran) anticoagulation of pediatric patients with heparin-induced thrombocytopenia. J Pediatr Hematol Oncol 1999;321:327.
22.
Wilhelm MJ, Schmid C, Kececioglu D, Mollhoff T, Ostermann H, Scheld HH: Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996;61:920–924.
23.
Zöhrer B, Zenz W, Rettenbacher A, Covi P, Kurnik K, Kroll H, Grubbauer HM, Muntean W: Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Paediatr 2001;90:765–771.
24.
Nguyen TN, Gal P, Ransom JL, Carlos R: Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:229–233.
25.
Ranze O, Rakow A, Ranze P, Eichler P, Greinacher A, Fusch C: Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced throm bocytopenia. Pediatr Crit Care Med 2001;2:175–177.
26.
Lischetzki G, Dittrich K, Topf H-G, Klinge J: Pediatric heparin-induced thrombocytopenia type II on haemodialysis (abstract P38). Haemostaseologie 2004;24:A48.
27.
Newall F, Barnes C, Ignjatovic V, Monagle P: Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003;39:289–292.
28.
Saxon BR, Black MD, Edgell D, Noel D, Leaker MT: Pediatric heparin-induced thrombocytopenia: management with danaparoid (Orgaran). Ann Thorac Surg 1999;68:1076–1078.
29.
Klenner AF, Lubenow N, Raschke R, Greinacher A: Heparin-induced thrombocytopenia in children: 12 new cases and a review of the literature. Thromb Haemost 2004;91:719–724.
30.
Ranze O, Ranze P, Magnani HN, Greinacher A: Heparin-induced thrombocytopenia in paediatric patients: a review of the literature and a new case treated with danaparoid sodium. Eur J Paediatr 1999;158(suppl 3):S130–S133.
31.
Spinler SA, Dager W: Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm 2003;60:S5–S11.
32.
Smythe M: A comparison of argatroban and lepirudin outcomes (abstract). Thromb Haemost 2003;1(suppl 1):P2041.
33.
Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126;1415–1423.
34.
Donovan PC: Heparin-induced thrombocytopenia: strategies for identification and treatment. Clin Rev 2001;11:93–105.
35.
Warkentin TE: Clinical picture of HIT; in Warkentin TE, Greinacher A (eds): Heparin-Induced Thrombocytopenia, ed 3. New York, Marcel Dekker, 2004, pp 53–106.
36.
Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121–2131.
37.
Greinacher A, Lubenow N, Hinz P, Ekkernkamp A: Heparin-induced thrombocytopenia (in German). Dtsch Ärztebl 2003;100:2220–2229.
38.
Albisetti M, Andrew M: Low molecular weight heparin in children. Eur J Pediatr 2002;161:71–77.
39.
Greinacher A, Warkentin TW: Treatment of heparin-induced thrombocytopenia; in Warkentin TE, Greinacher A (eds): Heparin- Induced Thrombocytopenia, ed 3. New York, Marcel Dekker, 2004, pp 335–370.
40.
Ranze O, Greinacher A: Current treatment concepts in heparin-induced thrombocytopenia (in German). Dtsch Med Wochenschr 1999;124:865–873.
41.
Monagle P, Michelson AD, Bovill E, Andrew M: Antithrombotic therapy in children. Chest 2001;119(1 suppl):344S–370S.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.